DR3 on the Main Stage: Shattuck Labs Puts SL-325 in the Spotlight as 2025 Results Take Shape

Analysis by a veteran finance writer, channeling the subtle wit of a market observer

Shattuck Labs, ticker STTK, released its fourth-quarter and full-year 2025 results alongside a detailed look at its DR3-blocking antibody program, led by SL-325. The filing emphasizes early-stage clinical progress and corporate updates, with the most concrete near-term milestone being data readouts from a Phase 1 program expected in the second quarter of 2026. Readers will want to see the actual EPS, EPS consensus, earnings surprise, and revenue forecast in the forthcoming earnings release, but the current document focuses on pipeline timing, safety signals, and management execution.

Key takeaways

Pipeline focus: SL-325, a DR3 blocking antibody, is advancing through Phase 1 with six single-ascending dose cohorts completed and full MAD cohort enrollment targeted for completion in Q2 2026. Data on safety, tolerability, pharmacokinetics, and receptor occupancy are slated for the second-quarter 2026 window.
Phase 2 timing: Subject to positive Phase 1 readouts and regulatory alignment, Shattuck plans to initiate a Phase 2 trial of SL-325 in Crohn's disease in the third quarter of 2026.
Bispecific program: The company continues to develop multiple DR3-based bispecific antibodies; lead bispecific has entered IND-enabling activities, with targets to be disclosed and development timelines outlined in the first half of 2026.
Corporate updates: Michael Choi, M.D., joined as Vice President of Clinical Development in November 2025, bringing additional clinical development leadership to the program.
Recent events: Shattuck participated in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with management engaging in one-on-one meetings and presenting program highlights.

Pipeline and milestones: what to watch

SL-325 sits at the center of Shattuck’s narrative about being a potentially first-in-class and best-in-mechanism DR3 blocking antibody for inflammatory and immune-mediated diseases, including Crohn's disease and ulcerative colitis. The company reports that the Phase 1 trial is ongoing, with six SAD cohorts completed and MAD enrollment proceeding, all designed to inform the dose and schedule for subsequent trials. The forthcoming readouts are positioned as the pivotal data point for the Phase 2 decision, with CRO/commercial considerations likely to hinge on PK, receptor occupancy duration, and tolerability signals.

The Phase 2 plan for Crohn’s disease is contingent on the Phase 1 outcomes and regulatory alignment. If Phase 1 demonstrates a favorable safety profile and meaningful pharmacodynamic signals, a Crohn’s program could be the near-term catalyst. Separately, the company’s broader DR3 bispecific strategy remains in early development, with IND-enabling activities underway and target specifics to be disclosed in 2026.

Management moves and corporate highlights

The addition of Dr. Michael Choi as Vice President of Clinical Development in November 2025 signals a sharpened clinical execution focus. His background—advancing inflammatory bowel disease programs and leadership roles at prior companies—appears calibrated for accelerating the Phase 1/Phase 2 readouts Shattuck is chasing. This kind of leadership shift often foreshadows an emphasis on delivering robust clinical data and aligning development milestones with capital markets expectations.

Recent events and investor-facing cadence

At the Piper Sandler 37th Annual Healthcare Conference, Shattuck’s management outlined the current clinical program status and near-term milestones. Communications like these help anchor expectations around data readouts in Q2 2026 and a potential Phase 2 initiation in late 2026, providing a framework for analysts to model the EPS implications of eventual licensing or collaboration discussions, even if those implications are far from immediate.

Outlook: what this portends for Shattuck and peers

The story here is timing. SL-325’s Phase 1 durability and the trajectory toward a Phase 2 readout in Crohn’s disease will be a focal point for investors monitoring revenue forecast paths for a biotech in early clinical stages. In the near term, absence of disclosed earnings numbers means attention will center on clinical milestones, safety signals, and the speed with which Shattuck can translate early pharmacodynamic data into a viable development plan.

For sector peers, Shattuck’s progress on a DR3 axis program adds to the growing interest in disease-modifying strategies for inflammatory diseases. If SL-325 demonstrates clean safety and encouraging receptor occupancy dynamics, collaborations or out-licensing discussions could accelerate downstream value realization—an outcome that would matter more to investors than any single quarterly EPS headline. Conversely, delayed readouts or safety concerns could tighten funding markets and reprice risk across early-stage biotech cohorts.

Bottom line

Shattuck Labs is positioning SL-325 as a potential cornerstone of its DR3 strategy, with Phase 1 data set to inform a Phase 2 path in Crohn’s disease, contingent on favorable safety and pharmacodynamics. The company’s stock- and press-release narrative now increasingly hinges on clinical cadence and execution, not on a near-term earnings surprise. As with many early-stage biotech stories, the next few quarters will be a test of whether the pipeline can translate early signals into credible development momentum and value creation for shareholders—while everyone waits to see the actual EPS and revenue forecast numbers that will follow in the formal earnings release.